Short communicationSimultaneous bioanalysis of Rasagiline (cas 136236-51-6) and its major metabolites in human plasma by LC–MS/MS: Application to a clinical pharmacokinetic study

Add time:09/04/2019    Source:sciencedirect.com

Rasagiline (cas 136236-51-6) is a selective, irreversible inhibitor of monoamine oxidase type-B (MAO-B) and has been used both as a monotherapy and in addition to levodopa in the treatment of Parkinson’s disease (PD). Rasagiline is metabolized by the cytochrome P450 (CYP) system, and the following three major metabolites with potential neuroprotective activity have been identified: 1-aminoindan (AI), 3-hydroxy-N-propargyl-1-aminoindan (3-OH-PAI) and 3-hydroxy-1-aminoindan (3-OH-AI). In this study, a novel liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed for the simultaneous determination of rasagiline and its major metabolites in human plasma. This method was validated in terms of specificity, linearity, precision, accuracy, recovery, matrix effect and stability. The validated method was then applied to a clinical pharmacokinetic study after the oral administration of 1 mg rasagiline mesylate tablets to six healthy Chinese volunteers.

We also recommend Trading Suppliers and Manufacturers of Rasagiline (cas 136236-51-6). Pls Click Website Link as below: cas 136236-51-6 suppliers

Prev:Protective effect of Rasagiline (cas 136236-51-6) in aminoglycoside ototoxicity
Next:Rasagiline (cas 136236-51-6) in Parkinson's Disease)